EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BridgeBio Pharma's enterprise value is $10,202.4 Mil.
BridgeBio Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-551.9 Mil. Therefore, BridgeBio Pharma's EV-to-EBITDA for today is -18.49.
The historical rank and industry rank for BridgeBio Pharma's EV-to-EBITDA or its related term are showing as below:
BBIO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.32 Med: -12.4 Max: -3.66
Current: -18.49
During the past 8 years, the highest EV-to-EBITDA of BridgeBio Pharma was -3.66. The lowest was -20.32. And the median was -12.40.
BBIO's EV-to-EBITDA is ranked worse than 100% of 459
companies
in the Biotechnology industry
Industry Median: 10.58
vs BBIO: -18.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
BridgeBio Pharma EV-to-EBITDA Historical Data
The historical data trend for BridgeBio Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BridgeBio Pharma's EV-to-EBITDA
For the Biotechnology subindustry, BridgeBio Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's EV-to-EBITDA falls into.
BridgeBio Pharma's current Enterprise Value is $10,202.4 Mil.
BridgeBio Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-551.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BridgeBio Pharma's PE Ratio (TTM) for today is calculated as:
BridgeBio Pharma's share price for today is $46.51.
BridgeBio Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of BridgeBio Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BBIO has been successfully added to your 